3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Specimen Handling
439
Magnetic Resonance Spectroscopy
341
pembrolizumab
288
Biopsy
241
Carboplatin
230
Cisplatin
193
Cyclophosphamide
185
Paclitaxel
164
Nivolumab
153
Gemcitabine
151
Bevacizumab
121
Radiotherapy
119
Dexamethasone
113
fludarabine
99
Pemetrexed
99
Fluorouracil
94
durvalumab
90
Doxorubicin
90
venetoclax
89
Docetaxel
89
Radiation
88
Oxaliplatin
88
Rituximab
87
atezolizumab
84
Leucovorin
79
Capecitabine
75
Prednisone
74
Lenalidomide
69
Etoposide
69
X-Rays
65
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Imlunestrant
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT07287098
2026-05-22
preEMBER
Eli Lilly and Company
Phase 2
Not yet recruiting
600 enrolled